drugset / Trial / NCT06620848

A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.

NCT06620848

Phase 2 Recruiting 49 enrolled Shanghai Zhongshan Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study was designed to evaluate the efficacy and safety of HRS-4642 monotherapy or in combination with adebrelimab in the treatment of advanced biliary tract tumor patients.

Timeline

Start
2024-11-21
Primary completion
2026-12-31
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Adebrelimab Monoclonal antibody
Subject HRS-4642 Unknown

Indications